Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Arrowhead Pharmaceuticals, Inc. (ARWR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
36.21+1.06 (+3.02%)
At close: 04:00PM EDT
36.21 0.00 (0.00%)
After hours: 04:34PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close35.15
Open36.01
Bid31.68 x 1200
Ask36.21 x 1300
Day's Range33.90 - 36.64
52 Week Range27.87 - 93.66
Volume730,997
Avg. Volume800,931
Market Cap3.785B
Beta (5Y Monthly)1.36
PE Ratio (TTM)N/A
EPS (TTM)-1.36
Earnings DateMay 02, 2022 - May 06, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est80.45
  • Zacks Small Cap Research

    ARWR: Phase 3 PALISADE Study of ARO-APOC3 Underway…

    By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Cardiometabolic Programs Progressing Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has two late-stage cardiometabolic programs, ARO-APOC3 and ARO-ANG3. ARO-APOC3 is targeted to apolipoprotein C-III (APOC3), a component of very low-density lipoprotein (VLDL) and an inhibitor of lipoprotein lipase. This program is

  • Business Wire

    Arrowhead Pharmaceuticals Reports Fiscal 2022 Second Quarter Results

    PASADENA, Calif., May 10, 2022--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal second quarter ended March 31, 2022. The company is hosting a conference call today, May 10, 2022, at 4:30 p.m. ET to discuss the results.

  • Business Wire

    Arrowhead Breaks Ground on New Manufacturing Facility with Wisconsin Governor Tony Evers and Announces Receipt of Incentives

    PASADENA, Calif., May 09, 2022--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today held a groundbreaking ceremony in Verona, WI, on the site which will house a new approximately 160,000 square foot drug manufacturing facility and an approximately 125,000 square foot laboratory and office facility to support process development and analytical activities. The Company also announced that it received awards for up to $16 million in tax increment financing from the city of Verona, and up to $2.5 mi

Advertisement
Advertisement